Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATTR 01

Next Previous
Drug Profile

ATTR 01

Alternative Names: ATTR-01; TROCEPT-01

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Accession Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immune checkpoint protein inhibitors; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 15 Sep 2025 Accession Therapeutics plans a phase I trial for ATTR 01 for Cancer in 2025 (Accession Therapeutics pipeline, September 2025)
  • 07 Aug 2025 Accession Therapeutics re-initiates the phase I/II ATTEST trial in Solid tumours (Second-line therapy or greater) in United Kingdom, Spain (IV) (NCT06977737)
  • 08 Jun 2025 Accession Therapeutics suspends the phase I/II ATTEST trial in Solid tumours (Second-line therapy or greater) in United Kingdom, Spain (IV), due to assay validation (NCT06977737)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top